Processa Pharmaceuticals Faces Delisting Concerns
Ticker: PCSA · Form: 8-K · Filed: Feb 10, 2025 · CIK: 1533743
| Field | Detail |
|---|---|
| Company | Processa Pharmaceuticals, Inc. (PCSA) |
| Form Type | 8-K |
| Filed Date | Feb 10, 2025 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Processa Pharmaceuticals might get delisted - big trouble ahead.
AI Summary
Processa Pharmaceuticals, Inc. filed an 8-K on February 10, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on February 4, 2025. The company was formerly known as Heatwurx, Inc. until October 28, 2011.
Why It Matters
This filing indicates potential issues with Processa Pharmaceuticals' continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a severe event that can lead to significant stock price declines and operational challenges.
Key Players & Entities
- Processa Pharmaceuticals, Inc. (company) — Registrant
- Heatwurx, Inc. (company) — Former company name
- February 4, 2025 (date) — Earliest event reported
- February 10, 2025 (date) — Filing date
- October 28, 2011 (date) — Date of name change from Heatwurx, Inc.
FAQ
What specific listing rule or standard has Processa Pharmaceuticals failed to satisfy?
The filing does not specify the exact rule or standard that Processa Pharmaceuticals has failed to satisfy, only that a notice has been issued.
What is the potential impact of this notice on Processa Pharmaceuticals' stock trading?
A failure to satisfy continued listing rules can lead to delisting, which would mean the company's stock would no longer be traded on the exchange, severely impacting liquidity and value.
Has Processa Pharmaceuticals taken any steps to address the listing deficiency?
The provided text of the 8-K does not detail any specific actions taken by the company to address the deficiency.
When was the earliest event reported that led to this notice?
The earliest event reported in relation to this notice was on February 4, 2025.
What was Processa Pharmaceuticals' former name?
Processa Pharmaceuticals, Inc. was formerly known as Heatwurx, Inc.
Filing Stats: 729 words · 3 min read · ~2 pages · Grade level 13.4 · Accepted 2025-02-10 16:05:32
Key Financial Figures
- $1.00 — mmon stock had closed below the minimum $1.00 per share requirement for continued lis
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-25-005633.txt ( ) — 209KB
- pcsa-20250204.xsd (EX-101.SCH) — 3KB
- pcsa-20250204_lab.xml (EX-101.LAB) — 33KB
- pcsa-20250204_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Processa Pharmaceuticals, Inc. Date: February 10, 2025 By: /s/ Russell Skibsted Russell Skibsted Chief Financial Officer